Biodesix (NASDAQ:BDSX) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Biodesix (NASDAQ:BDSX) posted its quarterly earnings data on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.10), Fidelity Earnings reports.

BDSX traded down $1.74 on Wednesday, hitting $13.01. 197,971 shares of the company were exchanged, compared to its average volume of 98,684. Biodesix has a 12 month low of $10.85 and a 12 month high of $31.99. The company has a fifty day moving average price of $17.93.

Several research analysts have recently weighed in on BDSX shares. Morgan Stanley reduced their price objective on Biodesix from $25.00 to $23.00 and set an “overweight” rating for the company in a research report on Wednesday. Zacks Investment Research lowered Biodesix from a “hold” rating to a “sell” rating in a report on Friday, March 19th. Finally, Canaccord Genuity upped their target price on Biodesix from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, February 2nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Biodesix currently has a consensus rating of “Buy” and a consensus price target of $25.75.

About Biodesix

Biodesix, Inc operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions.

Read More: What is a management fee?

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with's FREE daily email newsletter.